Cooper Companies Shares Jump 7% on Record Q2 Revenue and Earnings Beat

NEW YORK — Shares of The Cooper Companies Inc. surged more than 7% Friday morning, climbing to around $66.60, after the medical device maker reported record second-quarter revenue and non-GAAP earnings that exceeded Wall Street expectations, marking the company’s tenth consecutive quarter of beating consensus estimates.

The strong results highlighted resilient demand for CooperVision contact lenses and steady performance in CooperSurgical despite broader market volatility. Investors rewarded the company’s execution and raised outlook confidence even as some analysts adjusted price targets downward on valuation grounds.

CooperCompanies reported fiscal second-quarter revenue of $1.082 billion, an 8% increase from the prior year and ahead of analyst estimates around $1.05 billion. Non-GAAP diluted earnings per share reached $1.21, topping consensus forecasts of $1.10.

“We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations,” said Al White, CooperCompanies’ President and CEO.

The performance comes as the company continues to benefit from premium lens demand in its vision care business and stabilizing trends in surgical products. Organic growth and margin improvements underscored operational efficiency gains from recent restructuring efforts.

Business Segment Performance

CooperVision, the company’s larger segment focused on contact lenses, drove much of the growth with solid gains in daily disposable and toric lenses. The unit continues to capitalize on consumer shifts toward healthier, more convenient vision correction options amid an aging population and rising myopia awareness globally.

CooperSurgical reported more modest growth, supported by fertility and women’s health products. While the segment faces competitive pressures, management highlighted progress in integrating acquisitions and optimizing the portfolio for higher-margin offerings.

Free cash flow remained healthy at $96.4 million for the quarter, providing flexibility for potential share repurchases, debt management or strategic investments. The company maintained its full-year non-GAAP EPS guidance in the range of $4.58 to $4.66.

Analyst Reactions and Valuation Adjustments

Several Wall Street firms responded to the results by tweaking price targets while largely maintaining ratings. Baird kept an Outperform rating but lowered its target from $98 to $85. Needham held a Buy rating with a reduced target from $101 to $86. Wells Fargo maintained Equal-Weight and cut its target to $66.

The consensus rating hovers around Hold with an average price target near $87, suggesting potential upside from current levels despite the post-earnings pop. Analysts continue to cite strong fundamentals in vision care but note risks from currency fluctuations, competitive dynamics and macroeconomic pressures on consumer spending.

Company Background and Market Position

The Cooper Companies operates globally through its two main units: CooperVision, a leader in soft contact lenses, and CooperSurgical, focused on women’s health, fertility and surgical devices. The company serves millions of patients worldwide and benefits from long-term demographic trends including population growth, aging and increasing focus on vision and reproductive health.

Recent strategic moves, including board appointments and portfolio optimization, aim to enhance long-term growth. The company has emphasized innovation in premium products and operational efficiencies to navigate a challenging healthcare environment.

Broader Industry Context

The medical device sector has shown resilience in 2026 despite inflationary pressures and supply chain challenges. Demand for elective procedures and daily-use products like contact lenses has remained stable, supporting companies with strong brand portfolios and recurring revenue streams.

CooperCompanies’ results stand out against a mixed backdrop for healthcare stocks, where some peers have faced margin compression or slower growth. The earnings beat provides positive momentum as the company heads into the second half of the fiscal year.

Outlook and Key Risks

Management expressed confidence in its ability to deliver consistent growth through innovation and market expansion. Key focus areas include advancing premium lens technologies and strengthening its position in high-growth surgical categories.

Potential headwinds include foreign exchange volatility, given the company’s international footprint, regulatory changes in healthcare and competition from larger players. A one-time litigation charge of $271.6 million impacted GAAP results but was excluded from non-GAAP metrics.

Investors will monitor upcoming quarterly updates for progress on guidance and any strategic announcements. The stock’s reaction Friday demonstrates continued faith in the company’s ability to execute amid a dynamic industry landscape.

Investment Implications

For long-term investors, CooperCompanies offers exposure to essential healthcare needs with a track record of earnings consistency. The current valuation, while adjusted by analysts, reflects optimism around core growth drivers. Short-term traders may view the post-earnings volatility as an opportunity depending on risk appetite.

The medical device space remains attractive due to innovation cycles and demographic tailwinds. CooperCompanies’ focus on recurring revenue from contact lenses provides stability compared to more cyclical surgical markets.

As markets digest the latest results, the company’s performance reinforces its position as a reliable performer in healthcare. Continued execution on margins and revenue growth will be critical to sustaining investor confidence in the months ahead.

Friday’s surge highlights the market’s positive response to clear operational success and forward-looking stability. With solid fundamentals and a proven ability to exceed expectations, CooperCompanies enters the next phase of fiscal 2026 with momentum.